ER-Positive Breast Cancer
SERMs and aromatase inhibitors have been proven to be excellent agents in the preventive setting for ER-positive breast cancer, but newer agents must be found specifically for ER-negative breast cancers, which mostly occur in premenopausal women.
The antimalarial drug hydroxychloroquine (HCQ) reverses resistance to tamoxifen in mice, according to investigators.
An inexpensive malaria drug could be the answer for some women who are not responding to their cancer treatment, according to a promising but preliminary animal study.
In estrogen receptor (ER)+ breast cancer, obesity is positively associated with breast cancer mortality only among pre-/peri-menopausal women, according to new research.
Younger women who smoke appear to be at increased risk for developing ER-positive breast cancer, according to research, but no association found for risk of triple-negative breast cancer.
Human breast tumors transplanted into mice are excellent models of metastatic cancer and are providing insights into how to attack breast cancers that no longer respond to the drugs used to treat them, according to research presented at the 2013 San Antonio Breast Cancer Symposium.
A phase 1 trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe and provides early evidence for antitumor activity.
As cholesterol is metabolized, a potent stimulant of breast cancer is created—one that fuels estrogen receptor (ER)-positive breast cancers, according to new research.
A type of mutation that develops after breast cancer patients take antiestrogen therapies has been identified. These mutations help to explain why patients often become resistant to these types of therapies.
The breast cancer index (BCI) was the only one of three methods compared that predicted the risk for recurrence in women treated for estrogen-receptor (ER)-positive breast cancer.
A specific change that occurs when breast cancer tumors become resistant to antiestrogen therapy might make the tumors susceptible to treatment with chemotherapy drugs.
Researchers have identified the signaling pathway that is overactivated in estrogen receptor (ER)-positive breast cancer cells that are resistant to hormone therapies such as tamoxifen, aromatase inhibitors, or fulvestrant.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Atypical Teratoid/rhabdoid Tumors: Challenges and Search for Solutions
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|